AI Revolutionizes Medicine: First AI-Created IBD Therapy Enters Human Trials
Absci Achieves a Major Milestone
Absci, a clinical-stage biotech company, has reached a significant achievement by starting a Phase I clinical trial for its new therapy. This therapy was developed entirely using generative artificial intelligence (AI) to treat irritable bowel disease. Sean McClain, the founder and CEO of Absci, expressed excitement about advancing into this new stage of drug development. This marks a pivotal moment for the company as it moves closer to bringing innovative treatments to market.
Integrating AI into Drug Development
Artificial intelligence has been gradually incorporated into the drug development process over the years. Despite its potential, few AI-developed drugs have successfully passed through all regulatory approvals. Absci is pioneering this field by using AI not just in parts of the process, but from the very beginning of drug design. This comprehensive use of AI aims to make the drug development process faster and more cost-effective.
Introducing ABS-101: A Breakthrough Therapy
ABS-101 is Absci's leading drug candidate, designed to treat irritable bowel disease by targeting the TL1A protein in immune cells. Developed using generative AI, ABS-101 was created from scratch and moved to clinical trials in just 24 months at a cost of $15 million. This is significantly faster and more affordable compared to the typical drug development timeline and budget. The therapy aims to reduce immune system overactivity, providing a new treatment option for patients.
Innovative Clinical Trial Design
The Phase I clinical trial for ABS-101 is unique in its design, utilizing a subcutaneous method of administration instead of the traditional intravenous drip. This approach allows the therapy to be self-administered by patients, bringing it closer to its final form from the start. The trial will involve approximately 40 healthy adult volunteers to assess the drug's safety and tolerability. Additionally, the study will monitor pharmacokinetics and pharmacodynamics to gather comprehensive data.
Looking Ahead: Future Drug Candidates
After ABS-101, Absci is preparing to enter clinical trials for its next candidate, ABS-201, which targets conditions such as hair loss and endometriosis. The company plans to begin Phase I trials for ABS-201 in the first half of next year. Absci's pipeline indicates a strong commitment to developing multiple therapies, leveraging AI to streamline the drug discovery and development process. This forward momentum positions Absci as a key player in the biotech industry.
Conclusion: Pioneering the Future of Medicine
Absci is at the forefront of integrating artificial intelligence into the drug development lifecycle. By successfully initiating Phase I trials for ABS-101, the company has demonstrated the potential of AI to revolutionize how new therapies are discovered and tested. With ongoing research and a robust pipeline, Absci is well-equipped to continue making strides in creating effective and affordable treatments. The company's innovative approach promises to bring significant advancements to the field of medicine.
Read the full article here:
zdnet.com